Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
DETAILED SECOND NON-FINAL ACTION
1. Applicant’s response filed on July 22, 2026 is acknowledged. Claims 1, 2, 5 and 7 have been amended. Claims 1-7 are currently pending.
Please note that the specification has the incorrect application number in the header. Instead of the appropriate application of 18/566,643 it has 19/131,046. Copied below for convenience.
PNG
media_image1.png
65
982
media_image1.png
Greyscale
Election/Restrictions
2. Applicant’s rebuttal and evidence as it pertains to the lack of unity in the application has been considered. Based upon the knowledge that the bacterial strain of Sugiyama is indeed different than the currently claimed bacterial strain; the previously withdrawn clams 4 and 6 are hereby rejoined and are now being prosecuted in this application. Therefore, claims 1-7 are currently under examination.
Objections Withdrawn
3. In view of Applicant’s amendments, the objection to the specification for the use of a trade name or a mark used in commerce is withdrawn.
4. In view of Applicant’s amendments, the objection to the disclosure for containing an embedded hyperlink and/or other form of browser-executable code is withdrawn.
5. In view of Applicant’s amendments, the objection to the disclosure for having minor informalities is withdrawn.
6. In view of Applicant’s amendments, the objection to claim 2 as it pertains to the following informalities is withdrawn.
There is an unnecessary coma after the word ‘composition’;
‘dinking’ should be ‘drinking’;
‘feed supplement contains the bacterial strain’ should be ‘a feed supplement containing the bacterial strain’.
7. In view of Applicant’s amendments, the objection to claim 3 for reciting “The composition” is withdrawn.
Rejections Withdrawn
8. In view of Applicant’s amendments, the rejection to claim 1 which is rendered vague and indefinite by the use of the phrase, in part “SNI3 bacterium strain deposited as NCAIM(P) B 001482” is withdrawn.
9. In view of Applicant’s arguments, the rejection of claim(s) 1-3 and 7 under 35 U.S.C. 102(a)(1) as being anticipated by Sugiyama; TW 201124090 A1; Published: 7/16/11 is withdrawn.
10. In view of Applicant’s arguments, the rejection of claim(s) 5 under 35 U.S.C. 103 as being unpatentable over Sugiyama; TW 201124090 A1; Published: 7/16/11 as applied to claims 1-3 and 7 above, and further in view of Jana et al., Food Chemistry, 2021 (available online 11/28/20); 342(128328): 1-13 is withdrawn.
Objections Maintained
11. The objection to claim 2 because ‘101-1011’ should be 101-1011’ is maintained for the reason set forth in the previous office action. Unless Applicant intends to claim 101-1011 CFUs. As of now this portion of the objection has not been addressed and no changes have been made. Clarification is requested or appropriate correction is required.
Rejections Maintained
Claim Rejections - 35 USC § 112
The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.
12. The rejection of claims 1-3, 5 and 7 under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention is maintained for the reasons set forth in the previous office action.
The deposit receipt is acknowledged. However, to satisfy the requirements of this rejection Applicant must also attest that the deposit has been made under the provisions of the Budapest Treaty, filing of an affidavit or declaration by applicant or assignees or a statement by an attorney of record who has authority and control over the conditions of deposit over his or her signature and registration number stating that the deposit has been accepted by the International Depository Authority under the provisions of the Budapest Treaty and that all restrictions upon public access to the deposit will be irrevocably removed upon the grant of a patent on this application. These requirements are necessary when deposits are made under the provisions of the Budapest Treaty as the Treaty leaves this specific matter to the discretion of each State. Amendment of the specification to recite the date of the deposit and the complete name and full street address of the depository is required.
As previously presented,
Independent claim 1 is drawn to Lactiplantibacillus plantarum SNI3 bacterium strain, deposited as NCAIM (P) B 001482.
Because it is not clear that cell lines possessing the properties of Lactiplantibacillus plantarum SNI3 bacterium strain, deposited as NCAIM (P) B 001482 are known and publicly available or can be reproducibly isolated from nature without undue experimentation and because the claims require the use of a suitable deposit for patent purposes a deposit in a public repository is required. Without a publicly available deposit of the above Lactiplantibacillus plantarum SNI3, one of ordinary skill in the art could not be assured of the ability to practice the invention as claimed. Exact replication of the cell line is an unpredictable event.
Applicant’s referral to the deposit of Lactiplantibacillus plantarum SNI3 on page 5 of the specification is an insufficient assurance that all required deposits have been made and all the conditions of 37 CFR 1.801-1.809 have been met.
If the deposit has been made under the provisions of the Budapest Treaty, filing of an affidavit or declaration by applicant or assignees or a statement by an attorney of record who has authority and control over the conditions of deposit over his or her signature and registration number stating that the deposit has been accepted by the International Depository Authority under the provisions of the Budapest Treaty and that all restrictions upon public access to the deposit will be irrevocably removed upon the grant of a patent on this application. These requirements are necessary when deposits are made under the provisions of the Budapest Treaty as the Treaty leaves this specific matter to the discretion of each State. Amendment of the specification to recite the date of the deposit and the complete name and full street address of the depository is required.
If the deposits have not been made under the provisions of the Budapest Treaty, then in order to certify that the deposits comply with the criteria set forth in 37 CFR 1.801-1.809, assurances regarding availability and permanency of deposits are required. Such assurance may be in the form of an affidavit or declaration by applicants or assignees or in the form of a statement by an attorney of record who has the authority and control over the conditions of deposit over his or her signature and registration number averring: (a) during the pendency of this application, access to the deposits will be afforded to the Commissioner upon request; (b) all restrictions upon the availability to the public of the deposited biological material will be irrevocably removed upon the granting of a patent on this application; (c) the deposits will be maintained in the public repository for a period of at least thirty years from the date of deposit or for the enforceable life of the patent of or for a period of five years after the date of the most recent request for the furnishing of a sample of the deposited biological material, whichever is longest; and (d) the deposits will be replaced if they should become nonviable or non-replicable.
In addition, a deposit of biological material that is capable of self-replication either directly or indirectly must be viable at the time of deposit and during the term of deposit. Viability may be tested by the repository. The test must conclude only that the deposited material is capable of reproduction. A viability statement for each deposit of biological material not made under the Budapest Treaty must be filed in the application and must contain: 1) The name and address of the depository; 2) The name and address of the depositor; 3) The date of deposit; 4) The identity of the deposit and the accession number given by the depository; 5) The date of the viability test; 6) The procedures used to obtain a sample if test is not done by the depository; and 7) A statement that the deposit is capable of reproduction. As well as a statement that removes restrictions to provide access to this strain upon granting of a patent has not been made, either in the instant Specification, nor in Applicant's Remarks.
One of the critical conditions of Deposit is defined in 37 CFR 1.808 requires that the deposit of biological material be made under two conditions: (A) access to the deposit will be available during pendency of the patent application making reference to the deposit to one determined by the Commissioner to be entitled thereto under 37 CFR 1.14 and 35 U.S.C. 122, and (B) with one exception, that all restrictions imposed by the depositor on the availability to the public of the deposited biological material be irrevocably removed upon the granting of the patent. Upon making this statement, the rejection under 35 USC 112, first paragraph will be withdrawn. This rejection can be obviated through perfection of the Deposit and amendment of the claims to clearly set forth the Deposited strains.
As a possible means for completing the record, applicant may submit a copy of the contract with the depository for deposit and maintenance of each deposit.
If the deposit was made after the effective filing date of the application for patent in the United States, a verified statement is required from a person in a position to corroborate that the Lactiplantibacillus plantarum SNI3 described in the specification as filed is the same as that deposited in the depository. Corroboration may take the form of a showing a chain of custody from applicant to the depository coupled with corroboration that the deposit is identical to the biological material described in the specification and in the applicant’s possession at the time the application was filed.
Applicant’s attention is directed to In re Lundack, 773 F.2d.1216, 227 USPQ (CAFC 1985) and 37 CFR 1.801-1.809 for further information concerning deposit practice.
Claim Rejections - 35 USC § 112
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
13. The rejection of claim 5 for lacking antecedent basis is maintained for the reasons set forth in the previous office action. The amendment does not provide sufficient antecedent basis as there is no preparation recited in claim 2 for which claim 5 depends. There remains insufficient antecedent basis for this limitation in the claim.
New Grounds of Objection and Rejection
Specification
14. The disclosure is objected to because of the following informalities: There are only 6 figures complete with descriptions. However, the specification discusses Figures 7-8 and 10-13, which are not presented in the application.
Additionally, in Example 4, it recites 1,11 times higher. It is not clear what is intended. Should it be 1.11 times higher or some other quotient?
Appropriate correction is required.
Applicant is encouraged to review the entire specification any make any necessary changes.
Claim Objections
15. Claims 4 and 6 are objected to because of the following informalities:
As it pertains to claim 4, “1,5-5 fold” should be “1.5-5 fold”.
As it pertains to claim 6, in the fourth line a comma is required after “to increase reproductive condition”.
Appropriate correction is required.
Claim Rejections - 35 USC § 101
35 U.S.C. 101 reads as follows:
Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.
16. Claims 1-3, 5 and 7 are rejected under 35 U.S.C. 101 because the claimed invention is directed to a judicial exception (i.e., a law of nature, a natural phenomenon, or a product of nature) without significantly more. The claims are directed to naturally occurring bacteria. The claims do not include additional elements that are sufficient to amount to significantly more than the judicial exception. Additional elements of a food acceptable carrier, nutrient, herbs, and mannose or equivalent are recited. However, none of these items alter the way in which Lactiplantibacillus plantarum functions and they themselves do not have any functional differences than their natural counterparts.
Consideration of the additional elements as a combination also adds no other meaningful limitations to the exception not already present when the elements are considered separately. Unlike the eligible claim in Diehr in which the elements limiting the exception are individually conventional, but taken together act in concert to improve a technical field, the claim here does not invoke any of the considerations that courts have identified as providing significantly more than an exception. Even when viewed as a combination, the additional elements fail to transform the exception into a patent-eligible application of that exception. Thus, the claim as a whole does not amount to significantly more than the exception itself.
Claim Rejections - 35 USC § 112
The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.
17. Claims 2, 4 and 6 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention.
The MPEP states that the purpose of the written description requirement is to ensure that the inventor had possession, as of the filing date of the application, of the specific subject matter later claimed. The MPEP lists factors that can be used to determine if sufficient evidence of possession has been furnished in the disclosure of the application. These include “level of skill and knowledge in the art, partial structure, physical and/or chemical properties, functional characteristics alone or coupled with a known or disclosed correlation between structure and function, and the method of making the claimed invention.”
The written description requirement for a claimed genus may be satisfied through sufficient description of a representative number of species by actual reduction to practice, disclosure of drawings, or by disclosure of relevant identifying characteristics, for example, structure or other physical and/or chemical properties, by functional characteristics coupled with a known or disclosed correlation between function and structure, or by a combination of such identifying characteristics, sufficient to show the Applicants were in possession of the claimed genus.
Claim 4 is drawn to a method to increase the reproductive condition by 10-25%, to increase the sperm count at least 10-25%, to increase the serum testosterone level 1.5-5 fold, and/or to decrease aggression and anxiety at least 10-25% on male vertebrate animals and men, comprising administering to one or more male vertebrate animals and/or one or more men an effective amount of a preparation comprising the composition of claim 2 (a composition containing the strain Lactiplantibacillus plantarum SNI3 deposited as NCAIM (P) B 001482, wherein the 1 gram or 1 milliliter of food supplement, drinking water, drinking juice, nutrient, forage, and/or food, a feed supplement contains said bacterial strain in concentration of 101-1011 CFU/ml and 101-1011 CFU/g respectively).
Claim 6 is drawn to a method to favorably alter the behavior of breeding animals and human males comprising administering to male vertebrate animals, breeding animals and/or human males and effective amount of the composition according to claim 2: to increase reproductive condition, to increase sperm count, to increase testosterone serum level, to increase lean muscle mass and decrease fat mass, and/or to decrease aggressivity and anxiety.
The specification does not adequately describe the invention as claimed. Example 1 describes the effect of the claimed strain on male mice where the mice were administered a dose of 1.5x106 CFU/ml for 4 weeks. Said example relies upon Figure 1 stating that is shows body weight content of the mice, however Figure 1 does not match this description. In fact figure 1 shows images of colonies and microscopic images after gram staining of Clostridium butylicum.
Example 2 is supposed to support aggressive behavior; however, the reliance of Figure 2 does not support decreasing aggressive behavior at all or by any particular level. Figure 2 describes decreasing weight gain. Oddly enough, the control actually gained the least amount of weight in comparison to the mice who were administered the claimed bacterial strain. As it pertains to Example 3, not only does Figure 3 deal with body fat ratios, in view of what is taught in the art as outlined below, marble burying does not necessarily correlate to a decrease in aggressivity and anxiety.
Example 4 is to demonstrate testis weight; however the data relied upon is the effect of B. intestine on blood lipids. The remaining examples (5-9) all rely upon data which has not been provided.
The disclosure requires an invention that increases the reproductive condition by 10-25%, increases the sperm count by at least 10-25%, increases the serum testosterone level 1.5-5 fold and decreases aggression and anxiety by at least 10-25% on male vertebrate animals and men. Additionally, the invention is to favorably alter the behavior of breeding animals and human males. The specification does not adequately support the methods as claimed. There are no instances where male vertebrate animals and men are administered an effective amount of a preparation comprising the composition containing the strain Lactiplantibacillus plantarum SNI3 deposited as NCAIM (P) B 001482 and results in having the efficacy as claimed.
Favorably altering a behavior is subjective and the increase of reproductive conditions by 10-25% and 1.5-5 fold has not been adequately described. Simply put there is no data or evidence to support the invention as claimed. Not only does the specification only rely upon the complete strain of Lactiplantibacillus plantarum SNI3 deposited as NCAIM (P) B 001482; there are no demonstrations of lysates, components or any metabolite capable of the functionality as claimed. Moreover, methods to favorably alter the behavior of breeding animals and human males is not adequately described.
This data is important in view of the state of the art, which teaches that staying active, minimizing stress, and making changes to diet and lifestyle may help support make fertility. Certain supplements may also be beneficial to increasing sperm count (see Bielinski, https://www.healthline.com/health/boost-male-fertility-sperm-count - takeaway, 2024, pages 1-8).
Moreover, Men’s wellness teaches that testosterone levels in males peak at 19 years and naturally decline with age. They decrease by an average of 1% to 2% each year after age 30, although they may stabilize in your 40s or beyond. Following a nutritious diet and healthy lifestyle can help optimize testosterone levels and promote overall health (see Mawer et al., 2025 https://www.healthline.com/nutrition/8-ways-to-boost-testosterone).
As it pertains to decreasing aggression Morin (Very Well Mind, 2026 https://www.verywellmind.com/anger-management-strategies-4178870) teaches that anger management strategies can help control emotional reactions and maintain healthy relationships. By recognizing what triggers your anger and practicing relaxation techniques, you can reduce stress and prevent harmful behaviors. Learn to assess whether your anger is aiding or obstructing your emotional well-being.
Lastly, anxiety can leave you feeling out of control and having different techniques and healthy coping mechanisms in your anxiety toolkit can make you feel more in control of your mind and feelings. Said toolkit can include deep breathing, putting a halt to negative thoughts, focus on your senses, having a mantra, adopting a positive outlook, connect with things that give you strength, soothing your body, and asking for help (see Cleveland clinic, 2025, https://health.clevelandclinic.org/how-to-calm-anxiety).
University of California v. Eli Lilly and Co., 43 USPQ2d 1398, 1404. 1405 held that:
...To fulfill the written description requirement, a patent specification must describe an invention and does so in sufficient detail that one skilled in the art can clearly conclude that "the inventor invented the claimed invention." Lockwood v. American Airlines Inc. , 107 F.3d 1565, 1572, 41 USPQ2d 1961, 1966 (1997); In re Gosteli , 872 F.2d 1008, 1012, 10 USPQ2d 1614, 1618 (Fed. Cir. 1989) (" [T]he description must clearly allow persons of ordinary skill in the art to recognize that [the inventor] invented what is claimed."). Thus, an applicant complies with the written description requirement "by describing the invention, with all its claimed limitations, not that which makes it obvious," and by using "such descriptive means as words, structures, figures, diagrams, formulas, etc., that set forth the claimed invention." Lockwood, 107 F.3d at 1572, 41 USPQ2datl966.
Adequate written description of the claimed invention must include sufficient description of at least a representative number of species by actual reduction to practice, reduction to drawings, or by disclosure of relevant, identifying characteristics sufficient to show that Applicant was in possession of the claimed genus. However, factual evidence of an actual reduction to practice has not been disclosed by Applicant in the specification; nor has Applicant shown the invention was “ready for patenting” by disclosure of drawings or structural chemical formulas that show that the invention was complete; nor has the Applicant described distinguishing identifying characteristics sufficient to show that Applicant were in possession of the claimed invention at the time the application was filed.
Therefore for all these reasons the specification lacks adequate written description, and one of skill in the art cannot reasonably conclude that Applicant had possession of the claimed invention at the time the instant application was filed.
Claim Rejections - 35 USC § 112
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
18. Claim 2 recites the limitation "wherein the 1 gram or 1 milliliter" in line two. There is insufficient antecedent basis for this limitation in the claim.
19. Claim 6 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
Said claim is rendered vague and indefinite by the use of the phrase “to favorably alter the behavior of breeding animals and human males”. It is unclear what is meant by said phrase, as it is not explicitly defined in the specification. What constitutes “favorably alter”? The term favorably is such a subjective term. What core features must be maintained for one to know that a behavior has been favorably altered? As written, it is impossible to determine the metes and bounds of the claimed invention.
Claim Rejections - 35 USC § 112
The following is a quotation of 35 U.S.C. 112(d):
(d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers.
The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph:
Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers.
20. Claim 3 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Said claims recites ‘wherein the preparation contains live Lactiplantibacillus plantarum SNI3 bacterium strain, heat killed bacterium. Bacterium lysate, any component of the bacterium and/or its metabolite. Claim 2 which it depends from also recites a composition comprising a Lactiplantibacillus plantarum SNI3 bacterium strain, deposited as NCAIM (P) B 001482. Claim 3 does not further limit claim 1 and 2. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements.
Conclusion
21. No claim is allowed.
22. Any inquiry concerning this communication or earlier communications from the examiner should be directed to LAKIA J JACKSON-TONGUE whose telephone number is (571)272-2921. The examiner can normally be reached Monday-Friday 930AM-530PM.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Anne Gussow can be reached at (571) 272-6047. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format.
For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/LAKIA J JACKSON-TONGUE/Examiner, Art Unit 1645 October 2, 2026
/BRIAN GANGLE/Primary Examiner, Art Unit 1645